FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.

Both FDA-approved systems previously received inpatient payments in August. 

Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.

Palliative care is a recommended part of heart failure management in the U.S., but consultation rates remain low. The trend appears to impact Black patients more than other races and ethnicities. 

Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.

Robotic-assisted aortic valve surgery may be a safe, effective alternative to TAVR when treating low- and intermediate-risk patients. A new analysis in The Annals of Thoracic Surgery explored this topic at length.

Boston Scientific has scooped up Cortex, a healthcare technology company launched by the venture capital firm Ajax Health in 2023, in a move that will expand its EP offerings.

CMS continues to show confidence in the benefits of baroreflex activation therapy with the Barostim device from CVRx.